Richard Anderson

Senior Director, MSAT
Fate Therapeutics

Richard has over 20 years of experience in the research, development, and manufacturing scale-up of cellular therapy, immunotherapeutic and vaccine products. He is currently Senior Director of Manufacturing Science and Technology for Fate Therapeutics, Inc., leading the development and implementation of scaled-up manufacturing processes for Fate’s iPSC-derived NK and T cell therapy products.  Prior to Fate, Richard led the research and development including the scale-up of cellular therapy products based on the NK92 natural killer cell line for ImmunityBio, Inc. Earlier in his career, Richard developed prophylactic and therapeutic vaccines against infectious diseases and cancer while working in biotechnology and pharmaceutical companies within Europe and the USA.  Richard obtained his Ph.D. in Biochemistry from Imperial College London and completed postdoctoral studies at the University of Oxford prior to commencing his career in the biopharmaceutical industry.